B. Riley Financial Reaffirms Buy Rating for Precigen (NASDAQ:PGEN)

Precigen (NASDAQ:PGEN – Get Free Report)‘s stock had its “buy” rating restated by research analysts at B. Riley Financial in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $11.00 price objective on the biotechnology company’s stock, down from their previous price objective of $12.00. B. Riley Financial‘s price objective points to a potential upside of 142.29% from the stock’s current price.

A number of other brokerages have also issued reports on PGEN. Raymond James Financial set a $12.00 target price on Precigen in a research report on Thursday, November 5th. HC Wainwright increased their price target on Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Thursday, October 15th. Wall Street Zen raised Precigen from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 8th. Finally, Zacks Research downgraded Precigen from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $13.25.

View Our Latest Stock Analysis on PGEN

Precigen Price Performance

Shares of NASDAQ:PGEN opened at $4.54 on Monday. Precigen has a one year low of $3.04 and a one year high of $8.98. The stock has a fifty day moving average of $6.74 and a 200-day moving average of $5.28. The company has a market capitalization of $1.63 billion, a PE ratio of 45.40 and a beta of 1.01. The company has a debt-to-equity ratio of 1.12, a quick ratio of 4.83 and a current ratio of 5.58.

Precigen (NASDAQ:PGEN – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. The business had revenue of $74.15 million during the quarter, compared to analyst estimates of $71.55 million. Precigen had a return on equity of 57.93% and a net margin of 15.55%. The company’s revenue was up 2437.6% compared to the same quarter last year. During the same period last year, the company posted ($1.06) EPS. As a group, equities analysts anticipate that Precigen will post 0.23 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Jeffrey Kindler sold 185,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $7.44, for a total value of $1,376,400.00. Following the completion of the transaction, the director owned 17,100 shares of the company’s stock, valued at approximately $127,224. This trade represents a 91.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Rutul Shah sold 34,658 shares of Precigen stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $7.50, for a total transaction of $259,935.00. Following the transaction, the chief operating officer owned 465,012 shares in the company, valued at approximately $3,487,590. The trade was a 6.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 235,000 shares of company stock valued at $1,751,400 in the last ninety days. Company insiders own 41.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Entropy Technologies LP acquired a new stake in Precigen during the 3rd quarter worth about $500,000. Jump Financial LLC purchased a new position in Precigen during the 3rd quarter valued at about $2,511,000. Marshall Wace LLP purchased a new position in Precigen during the 3rd quarter valued at about $432,000. First Trust Advisors LP grew its stake in Precigen by 30.2% during the 3rd quarter. First Trust Advisors LP now owns 2,623,975 shares of the biotechnology company’s stock valued at $22,461,000 after acquiring an additional 609,316 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Precigen by 708.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 459,783 shares of the biotechnology company’s stock valued at $3,936,000 after purchasing an additional 402,901 shares during the period. Hedge funds and other institutional investors own 33.51% of the company’s stock.

About Precigen

(Get Free Report)

Precigen, Inc. is a biotechnology company focused on developing gene and cell therapies, including engineered immunotherapies. The company is based in Germantown, Maryland, and its roots include Intrexon, which adopted the Precigen name in 2020. Its approved product, PAPZIMEOS (zopapogene imadenovec-drba), is a gene therapy for adults with recurrent respiratory papillomatosis, a rare condition associated with human papillomavirus types 6 and 11. Precigen is also developing investigational therapies for cancers and other diseases.

Further Reading

Analyst Recommendations for Precigen (NASDAQ:PGEN)

Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.